LCAT and hepatocellular carcinoma: In summary, we constructed a novel risk model based on six DNL-related genes (G6PD, LCAT, SERPINE1, SOAT2, CYP2C9, and UGT1A10) that demonstrates robust performance in prognostic stratification, immune cell infiltration, and immunotherapy response prediction in HCC patients.